Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma

NCT01193842 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01193842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01193842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
October 6, 2010
Completion date
May 19, 2022
Enrollment
107 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related plasmablastic lymphoma, aids-related primary effusion lymphoma, ann arbor stage i diffuse large b-cell lymphoma, ann arbor stage i grade 3 follicular lymphoma, ann arbor stage ii diffuse large b-cell lymphoma, ann arbor stage ii grade 3 contiguous follicular lymphoma, ann arbor stage ii grade 3 non-contiguous follicular lymphoma, ann arbor stage iii diffuse large b-cell lymphoma, ann arbor stage iii grade 3 follicular lymphoma, ann arbor stage iv diffuse large b-cell lymphoma, ann arbor stage iv grade 3 follicular lymphoma, hiv infection, plasmablastic lymphoma, primary effusion lymphoma, recurrent diffuse large b-cell lymphoma, recurrent grade 3 follicular lymphoma